Al Musella, DPM President, Musella Foundation For Brain Tumor Research & Information, Inc.
-
November 22, 2021
Using Virtual Trials to Screen for Potential Glioblastoma Therapies
With: Al Musella, DPMThe existing drug development system “has failed miserably” for people with glioblastoma brain tumors, according to Al Musella, DPM, President of the Musella Foundation for Brain Tumor Research & Information, Inc. In partnership with Cancer Commons, his organization’s Brain Tumor Virtual Trial aims to speed discovery of promising new glioblastoma treatments. Curious Dr. George: How might your Virtual Trial approach speed the process toward… Read more »
-
October 1, 2020
How an Expert Would Treat His Own Glioblastoma
With: Al Musella, DPMTwo years ago, our Curious Dr. George asked Al Musella, DPM, what he would do if he were diagnosed with glioblastoma multiforme (GBM). Here, he revisits that question. Dr. Musella is President of the Musella Foundation For Brain Tumor Research & Information, Inc. Curious Dr. George: You direct an established foundation that supports research and information about brain tumors. What would you do if… Read more »
-
September 17, 2018
Options to Treat a Glioblastoma
With: Al Musella, DPMPlease see our updated version of this article from Oct 1, 2020. A Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY; email: musella@virtualtrials.com, phone: 888-295-4740 Q: You direct an established foundation that supports research and information about brain tumors. What would you do if you yourself were diagnosed with a glioblastoma multiforme (GBM)? A: Now… Read more »
-
July 16, 2018
Proposed FDA “Conditional Approval”- More Details
With: Marty Tenenbaum, PhDAl Musella, DPMA Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY, and Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Originally published May 10, 2017 Q: Your April 5, 2017 blog post that proposed a new “Conditional” category for FDA drug approval elicited a number of positive and negative responses. Please explain the proposal in more detail… Read more »
-
July 2, 2018
A Proposed New FDA Drug Approval Pathway: “Conditional”
With: Marty Tenenbaum, PhDAl Musella, DPMA Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY, and Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Originally published April 5, 2017 Q: The delay time from discovery/observation, through validation to approval and distribution/use of new cancer treatments remains excessive. With promising experimental treatments, advanced computer technology and biostatistics, creative alternatives… Read more »